<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00105443</url>
  </required_header>
  <id_info>
    <org_study_id>100554</org_study_id>
    <secondary_id>2004-001773-26</secondary_id>
    <nct_id>NCT00105443</nct_id>
  </id_info>
  <brief_title>A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma</brief_title>
  <acronym>SHARP</acronym>
  <official_title>A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find
      out if sorafenib has any effect on patient reported outcomes. Find out if sorafenib prevents
      the growth of or shrinks liver tumors and/or their metastases. Determine the pharmacokinetics
      (PK) in patients with liver cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following abbreviations were used in the Adverse Event section:

        -  international normalized ratio (inr)

        -  Common Terminology Criteria for Adverse Events (ctcae)

        -  Not Otherwise Specified (nos)

        -  Gastrointestinal (gi)

        -  Central nervous system (cns)

        -  Absolute Neutrophil Count (anc)

        -  Alanine aminotransferase (ALT)

        -  Aspartate aminotransferase (AST)

        -  Creatine phosphokinase (cpk)

        -  Gammaglutamyltransferase (ggt)

        -  Genitourinary (gu)

        -  Atrioventricular (av)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>from randomization to death due to any cause until an average 7.2 months later up to the data cut-off date approximately 19 months after start of enrollment</time_frame>
    <description>Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Symptomatic Progression (TTSP)</measure>
    <time_frame>from randomization to the first documented symptomatic progression until an average 4.8 months later up to the data cut-off date approximately 19 months after start of enrollment</time_frame>
    <description>TTSP was defined as the time from randomization to the first documented symptomatic progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>from randomization to disease progression based on radiological assessment until an average 2.8 months later up to the data cut-off date approximately 19 months after start of enrollment</time_frame>
    <description>TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control (DC)</measure>
    <time_frame>time from randomization to end of treatment up to the data cutoff date approximately 19 months after start of enrollment</time_frame>
    <description>The DC is defined as the number of subjects with a best response rating of complete response (CR), partial response (PR), or stable disease (SD) that is maintained at least 28 days from the first manifestation of that rating. Definitions: CR = disappearance of all clinical and radiological tumor lesions; PR = at least 30% decrease in sum of the longest diameters of tumor lesions; SD = neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire</measure>
    <time_frame>from randomization to end of treatment up to the data cutoff date approximately 19 months after start of enrollment</time_frame>
    <description>PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">602</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (Nexavar, BAY43-9006)</intervention_name>
    <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.</description>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages eligible for study: 18 years and above, Genders eligible for study: both

          -  Patients who have a life expectancy of at least 12 weeks

          -  Patients with histologically or cytologically documented Hepatocellular Carcinoma
             (HCC)

          -  Patients must have at least one tumor lesion that meets both of the following
             criteria: (1) Accurately measured in at least one dimension according to RECIST
             (Response Evaluation Criteria in Solid Tumors) (2) Not previously treated with local
             therapy

          -  Patients who have an ECOG (Eastern Cooperative Oncology Group) PS (Performance Status)
             of 0, 1, or 2

        Exclusion Criteria:

          -  Previous or concurrent cancer that is distinct in primary site or histology from HCC,
             EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder
             tumors (Ta [Noninvasive papillary carcinoma], Tis [Carcinoma in situ: &quot;flat tumor&quot;] &amp;
             T1 [Tumor invades subepithelial connective tissue]). Any cancer curatively treated &gt; 3
             years prior to entry is permitted

          -  Renal failure requiring hemo- or peritoneal dialysis

          -  History of cardiac disease

          -  Active clinically serious infections

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Known central nervous system tumors including metastatic brain disease

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054-4502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92668-3298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510-8019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-2000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030-3876</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-1502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pilar</city>
        <state>Buenos Aires</state>
        <zip>B1629AHJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bueno Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1417DTB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1120AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1145ADP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel de Tucumán</city>
        <state>Tucuman</state>
        <zip>T4000GTB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel de Tucumán</city>
        <state>Tucuman</state>
        <zip>T4000HXU</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90619900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <zip>30180090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <zip>30380490</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Chile</city>
        <state>Santiago</state>
        <zip>833-0024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago Región Metropolitana</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes Cedex</city>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haidari</city>
        <state>Attica</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>540 07</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>54639</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>84801</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Forlì</city>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>México, D.F.</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>México, D.F.</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington South</city>
        <zip>6001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Comas Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima Cercado</city>
        <zip>LIMA 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <zip>LIMA 34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-878</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300223</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Craiova Dolj</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirov</city>
        <zip>610002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>105 203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>111 020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>113 811</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>129 010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>195 067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tolgliatti</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cruces/Barakaldo</city>
        <state>Bilbao</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Gallen</city>
        <state>Sankt Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Avon</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX1 2JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <state>Stratchclyde</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <zip>NE2 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <results_reference>
    <citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.</citation>
    <PMID>18650514</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2005</study_first_submitted>
  <study_first_submitted_qc>March 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2005</study_first_posted>
  <results_first_submitted>December 11, 2009</results_first_submitted>
  <results_first_submitted_qc>September 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 27, 2010</results_first_posted>
  <last_update_submitted>October 24, 2014</last_update_submitted>
  <last_update_submitted_qc>October 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Cancer</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects with advanced hepatocellular carcinoma (HCC) were enrolled from Mar 10, 2005 to Apr 11, 2006 at 121 study centers in 21 countries around the Globe.</recruitment_details>
      <pre_assignment_details>After a 28 day screening period (902 subjects), 602 were randomized to Sorafenib (400 mg) twice daily (bid), or matching placebo. Majority of screen failures did not meet inclusion criteria. Efficacy population (intent-to-treat, ITT) was all randomized subjects (602), safety population was all subjects receiving at least 1 dose of study drug (599).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A1) Sorafenib (Nexavar, BAY43-9006) - no Open Label Phase</title>
          <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Note: Safety Data of participants in the arm presented here are reported in Reporting Groups (RG) RG1 and RG3 in the Safety section.</description>
        </group>
        <group group_id="P2">
          <title>A2) Sorafenib (Nexavar, BAY43-9006) - With Open Label Phase</title>
          <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study Note: Safety Data of participants in the arm presented here are reported in Reporting Groups (RG) RG1 and RG3 in the Safety section.</description>
        </group>
        <group group_id="P3">
          <title>B1) Placebo - no Open Label Phase</title>
          <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid).
Note: Safety Data of participants in the arm presented here are reported in Reporting Groups (RG) RG2 and RG4 in the Safety section.</description>
        </group>
        <group group_id="P4">
          <title>B2) Placebo First - Then Open Label Sorafenib Treatment Phase</title>
          <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.
Note: Safety Data of participants in the arm presented here are reported in Reporting Groups (RG) RG2, RG4, and RG5 in the Safety section.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="256"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="240">Subjects at Risk/Safety Population - partly in RG1 and RG3 (RG = Reporting Group for Safety Data)</participants>
                <participants group_id="P2" count="57">Subjects at Risk/Safety Population - partly in RG1 and RG3</participants>
                <participants group_id="P3" count="255">Subjects at Risk/Safety Population - partly in RG2 and RG4</participants>
                <participants group_id="P4" count="47">Subjects at Risk/Safety Population - partly in RG2 and RG4 as well as RG5</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228">228 participants directly switched to the Follow-up (FU) phase only</participants>
                <participants group_id="P2" count="57">47 participants continued with Sorafenib Open Label (OL); 10 first to FU prior to also switch to OL</participants>
                <participants group_id="P3" count="245">245 participants directly switched to the Follow-up (FU) phase</participants>
                <participants group_id="P4" count="47">36 participants switched to Sorafenib Open Label (OL); 11 first to FU prior to also switch to OL</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Radiological and symptomatic progression</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up and/or Open Label Nexavar</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="228">At start of period, 228 participants directly switched to Follow-up (FU)</participants>
                <participants group_id="P2" count="57">At start of period, 47 participants directly switched to Open Label (OL) Sorafenib treatment</participants>
                <participants group_id="P3" count="245">At start of period, 245 participants directly switched to Follow-up (FU)</participants>
                <participants group_id="P4" count="47">At start of period, 36 participants directly switched to Open Label (OL) Sorafenib treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Follow-up Only (no Open Label Treatment)</title>
              <participants_list>
                <participants group_id="P1" count="228">In parallel to &quot;Open Label treatment only&quot; phase</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="245">In parallel to &quot;Open Label treatment only&quot; phase</participants>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Open Label Treatment Only (no Follow-up)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="47">In parallel to &quot;Follow-up only&quot; phase; participants received Sorafenib 400 mg bid</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="36">In parallel to &quot;Follow-up only&quot; phase; participants received Sorafenib 400 mg bid</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Follow-up First, Then Open Label</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0">57 participants in total (47 + 10) received Open Label Sorafenib treatment (Subjects at Risk)</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0">47 participants in total (36 + 11) received Open Label Sorafenib treatment (Subjects at Risk)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="245"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="219"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression by clinical judgment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression, measurement proven</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression, recurrence, relapse</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Endpoint record not completed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Planned switch to OL; record incomplete</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with study medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reached ECOG 4</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switch to commercial drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib (Nexavar, BAY43-9006)</title>
          <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="299"/>
            <count group_id="B2" value="303"/>
            <count group_id="B3" value="602"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="11.2"/>
                    <measurement group_id="B2" value="66.3" spread="10.2"/>
                    <measurement group_id="B3" value="65.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Eastern Cooperative Oncology Group (ECOG)</title>
          <description>Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is a scale that measures how cancer affects a patient. The scale ranges from 0 (fully active) to 5 (dead). Subjects entering this study were to have an ECOG score of 0, 1 or 2.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 = fully active</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 = restricted in physical activity but ambulatory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = capable of selfcare</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor burden</title>
          <description>Tumor burden refers to the number of cancer cells, the size of a tumor, or the amount of cancer in the body and is also called the tumor load. Randomization was stratified by &quot;tumor burden&quot; assessment, ie, the presence of either macroscopic vascular invasion as determined by radiological assessment and/or extra-hepatic spread versus none.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.</description>
        <time_frame>from randomization to death due to any cause until an average 7.2 months later up to the data cut-off date approximately 19 months after start of enrollment</time_frame>
        <population>In this study the overall survival was measured for the ITT population from the date of randomization until the date of death due to any cause. For patients alive or lost to follow-up at the time of analysis, time to death was to be censored at their last date of follow-up, or at the data cut-off of 17 Oct 2006.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.</description>
          <population>In this study the overall survival was measured for the ITT population from the date of randomization until the date of death due to any cause. For patients alive or lost to follow-up at the time of analysis, time to death was to be censored at their last date of follow-up, or at the data cut-off of 17 Oct 2006.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324" lower_limit="286" upper_limit="405"/>
                    <measurement group_id="O2" value="241" lower_limit="206" upper_limit="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2 arms were compared using a 1-sided log-rank test with an overall alpha of 0.02 stratified by region, ECOG PS and “tumor burden”. In addition to the final analysis at the end of the study, 2 formal interim analyses of overall survival were planned. An alpha spending function was used to ensure that the false positive rate is less than or equal to 0.02 (1-sided). The study was stopped at the second interim analysis, the results of which are reported here.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00583</p_value>
            <p_value_desc>According to the pre-specified O’Brien-Fleming alpha spending function, the alpha value for this second interim analysis was 0.0073 (corresponding to a nominal value of 0.0077 after taking into account the first interim analysis).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.6931</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.5549</ci_lower_limit>
            <ci_upper_limit>0.8658</ci_upper_limit>
            <estimate_desc>This is the sorafenib to placebo hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Symptomatic Progression (TTSP)</title>
        <description>TTSP was defined as the time from randomization to the first documented symptomatic progression.</description>
        <time_frame>from randomization to the first documented symptomatic progression until an average 4.8 months later up to the data cut-off date approximately 19 months after start of enrollment</time_frame>
        <population>This analysis was for the ITT population. For subjects who had not progressed symptomatically at the time of interim analysis, TTSP was censored at the date of their last Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index (FHSI-8) questionnaire assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Symptomatic Progression (TTSP)</title>
          <description>TTSP was defined as the time from randomization to the first documented symptomatic progression.</description>
          <population>This analysis was for the ITT population. For subjects who had not progressed symptomatically at the time of interim analysis, TTSP was censored at the date of their last Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index (FHSI-8) questionnaire assessment.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" lower_limit="105" upper_limit="126"/>
                    <measurement group_id="O2" value="148" lower_limit="129" upper_limit="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2 arms were compared using a 1-sided log-rank test with an overall alpha of 0.005 stratified by region, ECOG PS and “tumor burden”. This was a co-primary endpoint with overall survival. No alpha-spending adjustments were necessary as it was only to be analyzed at the end of study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7676</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.0764</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8837</ci_lower_limit>
            <ci_upper_limit>1.3110</ci_upper_limit>
            <estimate_desc>This is the sorafenib to placebo hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP)</title>
        <description>TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation.</description>
        <time_frame>from randomization to disease progression based on radiological assessment until an average 2.8 months later up to the data cut-off date approximately 19 months after start of enrollment</time_frame>
        <population>The primary analysis of TTP for the ITT population was based on the independent radiological review for the interim analysis. The cut-off date chosen for the analysis of radiological progression events was 12 May 2006</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation.</description>
          <population>The primary analysis of TTP for the ITT population was based on the independent radiological review for the interim analysis. The cut-off date chosen for the analysis of radiological progression events was 12 May 2006</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" lower_limit="126" upper_limit="210"/>
                    <measurement group_id="O2" value="86" lower_limit="82" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>In the analysis of TTP, based on independent radiological review performed to review data up to 12 May 2006, the 2 treatment groups were compared using a 1-sided log rank test with an alpha of 0.025, stratified by region, ECOG PS, and “tumor burden”.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000007</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5764</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.4484</ci_lower_limit>
            <ci_upper_limit>0.7410</ci_upper_limit>
            <estimate_desc>This is the sorafenib to placebo hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control (DC)</title>
        <description>The DC is defined as the number of subjects with a best response rating of complete response (CR), partial response (PR), or stable disease (SD) that is maintained at least 28 days from the first manifestation of that rating. Definitions: CR = disappearance of all clinical and radiological tumor lesions; PR = at least 30% decrease in sum of the longest diameters of tumor lesions; SD = neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease.</description>
        <time_frame>time from randomization to end of treatment up to the data cutoff date approximately 19 months after start of enrollment</time_frame>
        <population>In this study, the DC for the ITT population was determined by independent radiological review and also by investigator assessment (both by using response evaluation criteria in solid tumors [RECIST])</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control (DC)</title>
          <description>The DC is defined as the number of subjects with a best response rating of complete response (CR), partial response (PR), or stable disease (SD) that is maintained at least 28 days from the first manifestation of that rating. Definitions: CR = disappearance of all clinical and radiological tumor lesions; PR = at least 30% decrease in sum of the longest diameters of tumor lesions; SD = neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease.</description>
          <population>In this study, the DC for the ITT population was determined by independent radiological review and also by investigator assessment (both by using response evaluation criteria in solid tumors [RECIST])</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease control rates were compared between treatment groups using the Cochran Mantel Haenszel (CMH) test with a 1-sided alpha of 0.025, adjusting for region, ECOG PS, and “tumor burden”.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001641</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-11.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.56</ci_lower_limit>
            <ci_upper_limit>-4.35</ci_upper_limit>
            <estimate_desc>Sorafenib minus placebo difference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire</title>
        <description>PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value.</description>
        <time_frame>from randomization to end of treatment up to the data cutoff date approximately 19 months after start of enrollment</time_frame>
        <population>In this study, the PRO was a tertiary efficacy variable assessed for the ITT population at Cycle 3 day 1 or, for those discontinuing prior to that visit, at end of study. It was summarized as number of patients with change from baseline &lt;8 or ≥8 points for each treatment group up to the cutoff date of 17 Oct 2006</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire</title>
          <description>PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value.</description>
          <population>In this study, the PRO was a tertiary efficacy variable assessed for the ITT population at Cycle 3 day 1 or, for those discontinuing prior to that visit, at end of study. It was summarized as number of patients with change from baseline &lt;8 or ≥8 points for each treatment group up to the cutoff date of 17 Oct 2006</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 3 day 1 change &lt;8 points</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 day 1 change ≥8 points</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Overall Survival</title>
        <description>Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.</description>
        <time_frame>from randomization to death due to any cause until an average 8.5 months later up to the data cut-off date approximately 23 months after start of enrollment</time_frame>
        <population>The OS data (ITT population) are descriptive only (no p-values) from the date of randomization to the date of death due to any cause. For patients alive at the time of analysis, time to death was censored at the date of last follow-up or at the data cutoff date of 09 Feb 2007 when subjects were given the option to crossover to sorafenib treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.</description>
          <population>The OS data (ITT population) are descriptive only (no p-values) from the date of randomization to the date of death due to any cause. For patients alive at the time of analysis, time to death was censored at the date of last follow-up or at the data cutoff date of 09 Feb 2007 when subjects were given the option to crossover to sorafenib treatment</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327" lower_limit="287" upper_limit="400"/>
                    <measurement group_id="O2" value="243" lower_limit="206" upper_limit="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Time to Symptomatic Progression (TTSP)</title>
        <description>TTSP was defined as the time from randomization to the first documented symptomatic progression</description>
        <time_frame>from randomization to the first documented symptomatic progression until an average 5.7 months later up to the data cut-off date approximately 23 months after start of enrollment</time_frame>
        <population>For subjects (in the ITT population) who had not progressed symptomatically at the time of interim analysis, TTSP was censored at the date of last FACT FHSI-8 questionnaire assessment (upon an interim review by the Data Monitoring Committee on 09 Feb 2007), when the study was considered positive for its primary endpoint, OS, and was stopped early.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Symptomatic Progression (TTSP)</title>
          <description>TTSP was defined as the time from randomization to the first documented symptomatic progression</description>
          <population>For subjects (in the ITT population) who had not progressed symptomatically at the time of interim analysis, TTSP was censored at the date of last FACT FHSI-8 questionnaire assessment (upon an interim review by the Data Monitoring Committee on 09 Feb 2007), when the study was considered positive for its primary endpoint, OS, and was stopped early.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" lower_limit="106" upper_limit="152"/>
                    <measurement group_id="O2" value="148" lower_limit="132" upper_limit="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Time to Progression (TTP)</title>
        <description>TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation.</description>
        <time_frame>from randomization to disease progression based on radiological assessment until an average 2.8 months later up to the data cut-off date approximately 23 months after start of enrollment</time_frame>
        <population>The independent radiological review as initially scheduled for the interim analysis did not continue after 12 May 2006. The primary analysis of TTP for the ITT population after 12 May 2006 up to the cutoff date of 09 Feb 2007 was based on the Investigator radiological assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation.</description>
          <population>The independent radiological review as initially scheduled for the interim analysis did not continue after 12 May 2006. The primary analysis of TTP for the ITT population after 12 May 2006 up to the cutoff date of 09 Feb 2007 was based on the Investigator radiological assessments</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" lower_limit="126" upper_limit="210"/>
                    <measurement group_id="O2" value="86" lower_limit="82" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Disease Control (DC)</title>
        <description>The DC is defined as the number of subjects with a best response rating of CR, PR, or SD that is maintained at least 28 days from the first manifestation of that rating.</description>
        <time_frame>from randomization to end of treatment up to the data cutoff date approximately 23 months after start of enrollment</time_frame>
        <population>The disease control rate for the ITT population was determined by independent radiological review and also by investigator assessment (both by using response evaluation criteria in solid tumors (RECIST) up to the cutoff date of 09 Feb 2007</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control (DC)</title>
          <description>The DC is defined as the number of subjects with a best response rating of CR, PR, or SD that is maintained at least 28 days from the first manifestation of that rating.</description>
          <population>The disease control rate for the ITT population was determined by independent radiological review and also by investigator assessment (both by using response evaluation criteria in solid tumors (RECIST) up to the cutoff date of 09 Feb 2007</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire</title>
        <description>PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value. At the cut-off date for this analysis, one more patient data has been gained.</description>
        <time_frame>from randomization to end of treatment up to the data cutoff date approximately 23 months after start of enrollment</time_frame>
        <population>In this study, the PRO was a tertiary efficacy variable assessed for the ITT population at Cycle 3 Day 1 or, for those discontinuing prior to that visit, at the end of study. It was summarized as number of patients with change from baseline &lt;8 to ≥8 points for each treatment group up to the cutoff date of 09 Feb 2007.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire</title>
          <description>PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value. At the cut-off date for this analysis, one more patient data has been gained.</description>
          <population>In this study, the PRO was a tertiary efficacy variable assessed for the ITT population at Cycle 3 Day 1 or, for those discontinuing prior to that visit, at the end of study. It was summarized as number of patients with change from baseline &lt;8 to ≥8 points for each treatment group up to the cutoff date of 09 Feb 2007.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 3 day 1 change &lt;8 points</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 day 1 change ≥8 points</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reporting Group (RG) 1 + 2: Data for Interim Analysis, cut-off Oct 17, 2006; RG 3: Data during and after unblinding (until Nov 21, 2008); RG 4: Data prior to date of unblinding (Feb 9, 2007); RG 5: Data after unblinding (Open Label; until Nov 21, 2008)</time_frame>
      <desc>RG 1 + 3 description: All subjects randomized to Sorafenib treatment; RG 2 + 4 description: All subjects randomized to Placebo before unblinding (when they were on Placebo, before they had the opportunity to switch to Sorafenib treatment); RG 5 description: All placebo subjects who switched to Sorafenib treatment after unblinding occurred.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib (Nexavar) Arm Double-Blind Phase (Interim Data Only)</title>
          <description>Reporting Group 1 (RG 1): All participants in Double-Blind phase randomized to Sorafenib treatment (data before Oct 17, 2006); Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Note: Safety Data presented here include participants listed in Arms A1 and A2 of the Participant Flow section.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm Double-Blind Phase (Interim Data Only)</title>
          <description>Reporting Group 2 (RG 2): All participants in Double-Blind phase randomized to Sorafenib-matching placebo (data before Oct 17, 2006); Sorafenib-matching placebo tablets were orally administered twice daily (bid).
Note: Safety Data presented here include participants listed in Arms B1 and B2 of the Participant Flow section.</description>
        </group>
        <group group_id="E3">
          <title>Sorafenib (Nexavar) Arm Complete (Incl. Open Label Phase)</title>
          <description>Reporting Group 3 (RG 3): All participants that initially were randomized to Sorafenib treatment (data before unblinding (= Double-Blind phase) and after unblinding (= Open Label phase)), until Nov 21, 2008); Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Note: Safety Data presented here include participants listed in Arms A1 and A2 of the Participant Flow section.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Arm, Complete Double-Blind Phase</title>
          <description>Reporting Group 4 (RG 4): All participants that initially were randomized to Placebo (data from Placebo patients before unblinding at Feb 09, 2007); Sorafenib-matching placebo tablets were orally administered twice daily (bid).
Note: Safety Data presented here include participants listed in Arms B1 and B2 of the Participant Flow section.</description>
        </group>
        <group group_id="E5">
          <title>Subjects Switching From Placebo to Sorafenib (Open Label Only)</title>
          <description>Reporting Group 5 (RG 5): Participants initially randomized to Placebo who switched to Sorafenib in Open Label phase (data after unblinding only, from Feb 09, 2007 until Nov 21, 2008); Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid). Note: Safety Data presented here include participants listed in Arm B2 of the Participant Flow section.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE v. 3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="185" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>inr</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>lymphatics - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>lymphedema-related fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>edema: head and neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>supraventricular arrhythmia, atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>conduction abnormality, av block - first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>supraventricular arrhythmia, sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>ventricular arrhythmia, ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>ventricular arrhythmia, ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>cardiac general - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>right ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>conduction abnormality, asystole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>conduction abnormality, av block-3rd degree (complete av block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>cardiac arrhythmia - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>ascites</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>gi - other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>perforation, gi, colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>stricture, gi, biliary tree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>ulcer, gi, duodenum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>ulcer, gi, stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>liver dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hepatobiliary - other</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>obstruction, gi, small bowel nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>perforation, gi, appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death not associated with ctcae term, death nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>death not associated with ctcae term, disease progression nos</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>death not associated with ctcae term, multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>death not associated with ctcae term, sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>constitutional symptoms - other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, back</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, abdomen nos</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, joint</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, bone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, neuralgia/peripheral nerve</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>syndromes - other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>not coded yet</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, chest/thorax nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>tumor flare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection (documented clinically), abdomen nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection (documented clinically), anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection (documented clinically), biliary tree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection (documented clinically), lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection (documented clinically), skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection (documented clinically), soft tissue nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection (documented clinically), upper airway nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection (documented clinically), urinary tract nos</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with normal anc, bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with normal anc, gallbladder (cholecystitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with normal anc, oral cavity-gums (gingivitis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with normal anc, peritoneal cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with normal anc, skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with normal anc, urinary tract nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with unknown anc, biliary tree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with unknown anc, lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with unknown anc, peritoneal cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with unknown anc, urinary tract nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with unknown anc, wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection (documented clinically), blood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with normal anc, anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with normal anc, appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with normal anc, pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with unknown anc, appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with unknown anc, blood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infection with unknown anc, bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>intraop injury, biliary tree - common bile duct</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>cpk</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>ggt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>musculoskeletal - other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>device/prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>muscle weakness, whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cns ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>mood alteration, depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>neuropathy: motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>neurology - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>obstruction, gu, ureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pulmonary - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dermatology - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>decubitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>wound complication, non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cns hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, abdomen nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, esophagus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, varices (esophageal)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, stomach</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, liver</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, lower gi nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, peritoneal cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, varices (rectal)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, upper gi nos</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage with surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage pulmonary, lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage pulmonary, pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>peripheral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>visceral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhage, gi, rectum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI-CTCAE v. 3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="259" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="281" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="271" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>ascites</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="166" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>mucositis (functional/symptomatic), oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>mucositis (clinical exam), oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>gi - other</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>liver dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hepatobiliary - other</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="144" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, back</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, abdomen nos</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, head/headache</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, joint</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, stomach</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>constitutional symptoms - other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, bone</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain, liver</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection - other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal - other</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>mood alteration, depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>voice changes</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dermatology - other</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

